KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Non Operating Investment Income (2019 - 2025)

Ionis Pharmaceuticals (IONS) has 14 years of Non Operating Investment Income data on record, last reported at $788000.0 in Q4 2025.

  • For Q4 2025, Non Operating Investment Income rose 130.69% year-over-year to $788000.0; the TTM value through Dec 2025 reached $10.2 million, up 453.76%, while the annual FY2025 figure was $10.2 million, 453.76% up from the prior year.
  • Non Operating Investment Income reached $788000.0 in Q4 2025 per IONS's latest filing, down from $29.9 million in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $29.9 million in Q3 2025 and bottomed at -$18.3 million in Q2 2025.
  • Average Non Operating Investment Income over 5 years is $430263.2, with a median of $718000.0 recorded in 2023.
  • Peak YoY movement for Non Operating Investment Income: tumbled 1495.03% in 2024, then surged 3302.5% in 2025.
  • A 5-year view of Non Operating Investment Income shows it stood at $5.2 million in 2021, then crashed by 37.08% to $3.3 million in 2022, then tumbled by 104.9% to -$161000.0 in 2023, then crashed by 1495.03% to -$2.6 million in 2024, then skyrocketed by 130.69% to $788000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Investment Income were $788000.0 in Q4 2025, $29.9 million in Q3 2025, and -$18.3 million in Q2 2025.